Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI

1 day ago 2

Unlock banal picks and a broker-level newsfeed that powers Wall Street.

TipRanks

Tue, Apr 1, 2025, 9:45 AM 1 min read

Evercore ISI notes that Vaxcyte (PCVX) missed 4 serotypes versus Prevnar20 successful the “all-important” babe data, adding that an “imperfect vaccine property merchandise connected the heels of Peter Marks resignation is conscionable pugnacious timing.” However, the expert contends that 3 of the 4 misses successful today’s Phase 2 are “narrow – and volition rather apt beryllium ok” successful a larger Phase 3 trial. The steadfast maintains an Outperform standing connected Vaxcyte shares, which are down $34.89, oregon 50%, to $34.57 successful aboriginal day trading pursuing the institution having shared topline results from its Phase 2 dose-finding survey evaluating the safety, tolerability and immunogenicity of VAX-24, the company’s 24-valent pneumococcal conjugate vaccine campaigner designed to forestall invasive pneumococcal disease, compared to Prevnar 20 successful steadfast infants.